Grifols
Grifols is the Catalan plasma-medicines group founded in 1909, whose immunoglobulins, albumin and clotting factors are used in supportive cancer care, and which has led phase 3 trials in cancer-related settings.
Overview
Grifols, headquartered in Sant Cugat del Vallès near Barcelona and founded in 1909, is one of the three largest plasma-derived medicines companies, producing immunoglobulins used for infection prevention in blood cancers, albumin and coagulation factors, alongside diagnostics. Its US arms Grifols Therapeutics and Grifols Biologicals appear on ClinicalTrials.gov as lead sponsors of phase 3 trials in cancer-related settings.
Similar pages
not linked directly; found by shared links- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyIntra-IMMUSG
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyJW Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.